Gamida Cell is a cell and immune therapy visionary. The company’s broad platform technology to expand functional cells in culture serves as the basis for unprecedented, life-saving cures for blood cancers such as leukemia, lymphoma and rare genetic diseases like sickle cell disease.

Currently in phase III clinical trial in hematological malignancies, Gamida Cell is well positioned to fill the unmet clinical needs of several potentially multibillion dollar markets.